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See Article, pages 1215–1221The management of hepatitis B virus (HBV) infection in preg-
nancy is complex. Because infection with HBV in infancy often
leads to chronic disease, prevention of perinatal or vertical trans-
mission is a major goal. Worldwide, vertical transmission
remains the most frequent route of infection, particularly in
endemic areas where up to 20% of women of childbearing age
may have HBV. These women constitute a reservoir for perinatal
transmission, which is associated with a very high rate of chro-
nicity [1–3]. Without immunoprophylaxis, up to 90% of infants
born to hepatitis B e antigen (HBeAg)-positive mothers become
HBV chronically infected. However, the maternal screening pro-
grams and universal vaccination in newborns with active and
passive immunoprophylaxis have dramatically reduced HBV
transmission rates. But even with the use of appropriate prophy-
laxis with HBV immunoglobulin (HBIG) and HBV vaccination, a
signiﬁcant risk of vertical transmission remains, particularly in
mothers with high viral loads and positive hepatitis B e antigen
(HBeAg) status. In one series of mothers with high viral loads, this
risk was as high as 28% [4]. An HBV DNA level greater than
107 copies/ml is an important risk factor for HBV transmission
[5,6]. Wiseman et al. [7] recently studied 298 chronically HBV-
infected women and their infants, who were vaccinated and
who received HBIG. The infants were tested for HBV at 9 months
of age and showed an HBV rate of 8.5% born to mothers with
virus levels greater than 8 log10 copies/ml. There is no indication
to perform a caesarian section to reduce HBV transmission if vac-
cination and HBIG are administered accordingly.
Factors that inﬂuence treatment choices in women of child-
bearing age include safety in pregnancy and breastfeeding, efﬁ-
cacy of the agent, its barrier to resistance, length of therapy,
and most important, the cause of treatment, i.e. treating the
mother because of an advanced liver disease or treating the
unborn child to prevent transmission.
If pregnancy is contemplated in near future, it may be prudent
to delay therapy until after the child is born. This approach
requires a careful assessment of the degree of hepatic activity
and ﬁbrosis. Although it is not to be used in the pregnant woman,
interferon can be used in the woman of childbearing age, becauseJournal of Hepatology 20
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often results in clinical remission [8]. This scenario is in contrast
to the oral antiviral agents that generally require long-term ther-
apy and result in lower rates of stable HBeAg seroconversion and
some HBsAg loss only in HBeAg positive patients [9]. For those
who require therapy, it is advisable to discuss the issue of preg-
nancy before starting the treatment.
No antiviral agent has been approved for use in pregnancy.
Thus, when a woman on HBV antiviral therapy becomes preg-
nant, a decision needs to be made whether she should continue
therapy for the duration of the pregnancy or if therapy should
be withdrawn immediately. As with all decisions during preg-
nancy, the health of the mother and the fetus must be considered
independently. From the perspective of the fetus, the major con-
cern is the risk of exposure to medication during early embryo-
genesis. From the perspective of the mother, the major issue is
whether stopping or switching medication will adversely affect
both short- and long-term liver disease outcomes. In general, if
the mother is known to have signiﬁcant ﬁbrosis, therapy should
be continued because the risk of ﬂare with withdrawal of therapy
could result in reactivation and even decompensation of her liver
disease. This effect on the mother’s health could also impact the
health of the fetus.
Decisions about initiating therapy during pregnancy again
must include consideration of the risks and beneﬁts for the
mother and the fetus; furthermore, in which trimester the ther-
apy should be started must be considered, too. Interferon has
antiproliferative actions and is contraindicated during pregnancy.
Furthermore, all polymerase inhibitors interfere with the replica-
tion of mitochondrial DNA, and this can result in mitochondrial
toxicity leading to the lactic acidosis syndrome [10]. Although
lactic acidosis syndrome is very uncommon in adults, less is
known about the potential ramiﬁcations of mitochondrial toxic-
ity in the developing fetus. These effects may be more diverse,
because toxicity may affect organogenesis.
Of the nucleoside and nucleotide analogs indicated for the
treatment of chronic HBV infection, all are classiﬁed as Food
and Drug Administration (FDA) pregnancy risk category C except
for tenofovir and telbivudine, which are category B. Most human
experience with antiviral drug therapy in pregnancy has been
with lamivudine. More than 4600 women have been exposed to
the drug during their second or third trimester [11] and reported
to the Antiretroviral Pregnancy Registry (APR). The APR monitors
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women who have been exposed to lamivudine, tenofovir,
emtricitabine, or other antiviral drugs. Despite the large number
of enrolled patients and reassuring results showing no signiﬁcant
increase in birth defects, there are limitations, including short fol-
low-up and recording only defects identiﬁed at birth. Develop-
mental anomalies (e.g. cardiac or neurologic defects) identiﬁed
at a later date may therefore be omitted. Similar registries spon-
sored by the pharmaceutical industry have been severely limited
by poor enrollment and provide little meaningful data. For the
APR, no signiﬁcant difference was reported in the rate of adverse
outcomes if the initial exposure of any HBV drug was in the ﬁrst
trimester (2.7%) compared to the second or third trimester (2.5%)
of pregnancy or compared to a non HIV nontreated general
population.
Even though lamivudine is classiﬁed as FDA pregnancy risk cat-
egory C, it is associated with the risk of birth defects that is not
higher than the baseline birth defect rate. A meta-analysis of 10
randomized clinical trials (RCTs) examining 951HBVcarriermoth-
ers was reported to evaluate the efﬁcacy of lamivudine in reducing
in utero transmission of HBV [12]. The RCTs evaluated included
newborns who received immunoprophylaxis at birth and women
who were treated with lamivudine from 24 to 32 weeks of gesta-
tion, until delivery to 1 monthpost-delivery. Newborns in the lam-
ivudine group had a 13–24% signiﬁcantly lower incidence of
intrauterine exposure and a lower perinatal infection rate at 9–
12 months. This report was limited by the quality of the studies
included. On the other hand, in a recent poster presented at EASL
2011 in Berlin [13], Ayres et al. showed that although the therapy
with lamivudine achieved an HBV DNA load reduction of
3 log10 IU/ml, in 20% of the pregnant women, the viral load
remained high (>1  107 IU/ml) and resistant mutations were
detectable only after three months of therapy, calling for more
potent antiviral drugs to be used to prevent transmission.
Of the two agents classiﬁed as FDA pregnancy risk category B,
only tenofovir received this classiﬁcation based on the data col-
lected in human exposure, so far. There have been no other pub-
lished studies using entecavir, adefovir, or emtricitabine for
preventing HBV vertical transmission, and these drugs should
be switched immediately, if a woman becomes pregnant.
The experience with tenofovir in pregnant women consists of
606 women in their ﬁrst trimester and 336 in their second trimes-
ter from theAPR. The rate of birth defects associatedwith tenofovir
ranges from 1.5% (second-trimester use) to 2.3% (ﬁrst-trimester
use), which is again similar to the background rate. Telbivudine
received its pregnancy risk category B rating based on animal stud-
ies; there were few human pregnancy registry data up to now.
In this issue of the Journal of Hepatology, Han et al. present a
prospective study [14] that evaluates the efﬁcacy of telbivudine
for preventing HBV newborn infection performed in 230 pregnant
HBsAg positive patients with HBV DNA levels of >1.0  106
copies/ml. The study shows that telbivudine plus vaccination is
superior to HBIG and HBV vaccines only in newborns to prevent
HBV transmission (0% vs. 8%). This study reconﬁrms data from a
recent study of 31 pregnant women in China, treatedwith telbivu-
dine started at weeks 28–32 of pregnancy and continued to
30 days postpartum [15]. All babies received active and passive
immunoprophylaxis. The infection rate was 0% in those treated
with telbivudine and 13.3% in the untreated controls.
The advantages of the study by Han et al. are the use of tel-
bivudine, a more potent antiviral drug than lamivudine with a
lower risk of HBV drug resistance and the inclusion of a large1172 Journal of Hepatology 2011number of pregnant HBsAg positive women. The disadvantages
are the short follow up, only seven months after delivery, and
the lack of results of virologic breakthrough and resistance data.
Furthermore, it is not a randomized study, patients were allo-
cated depending on their own wishes and prophylaxis was
started either during the second trimester or during the third tri-
mester but without a deﬁnitive time point. It is unclear whether
mothers with high levels of viremia started earlier compared to
those with low levels of viremia. The risk of HBV transmission
could have been analyzed even better in relation to the time of
starting prophylaxis in addition to HBV DNA levels. The primary
end point of the study was deﬁned as undetectable HBsAg and
HBV DNA at birth and at month 7. This is a short period of fol-
low-up to analyze HBV perinatal transmission, at least newborns
should be followed for 1 year. Nevertheless, this study is adding
very important information to our very limited knowledge of
safety of polymerase inhibitors in pregnant women and helps
to support the ‘‘B’’ rating of telbivudine.
Rather than switching agents, withdrawal of treatment for the
duration of pregnancy may be preferable in some cases, espe-
cially to the mother who wants to avoid any potential future risk
to the fetus. What would be the consequence to the mother of
stopping treatment completely? The natural history of chronic
HBV in pregnancy has not been well described. Limited data exist
to suggest that, rarely, severe complications of HBV occur late in
pregnancy, with reports of liver failure in previously asymptom-
atic individuals [16]. Data speciﬁcally addressing the risk of stop-
ping therapy during pregnancy are only anecdotal.
Overall, it appears that the risk of an adverse outcome with
continuing antiviral therapy during pregnancy is likely to be very
low. However, therapy could be discontinued with close observa-
tion of the mother to avoid continued fetal exposure during the
ﬁrst trimester, especially in the patient who does not have
advanced ﬁbrosis.
When deciding on starting therapy in the third trimester, the
perinatal transmission outcome of prior pregnancies should be
considered. If previous pregnancies did not result in perinatal
transmission, then a viral load of greater than 107 copies/ml
should be used to determine if therapy should be initiated (sim-
ilar to women who had no children). However, if perinatal trans-
mission did occur with a prior pregnancy, then the risk of
perinatal transmission in the current pregnancy is likely higher.
In such cases, strong consideration for initiating therapy in the
third trimester is recommended, regardless of the mother’s viral
load at the end of the second trimester.
Despite the position from the American Academy of Pediatrics
stating that breastfeeding is not contraindicated in naïve women
with HBV if HBIG and vaccination have been administered
accordingly [17], for mothers on antiviral therapy, breastfeeding
cannot be recommended. According to prescribing information,
it has not been recommended that women breastfeed their
infants while taking lamivudine or tenofovir, to avoid risking
postnatal transmission of HIV-1 infection (package inserts lami-
vudine and tenofovir). Although it is known that lamivudine
and tenofovir are both excreted into human breast milk, little is
known about the extent of exposure of antiviral agents during
breastfeeding. Thus, little is known about the overall safety of
breastfeeding in this setting.
In summary, treatment of HBV infection during pregnancy
remains a challenge, the risks and beneﬁts must be weighed care-
fully and there are still numerous gaps in our knowledge. Thevol. 55 j 1171–1173
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beneﬁts of treatment appear to be most pronounced in cases with
high maternal viremia to prevent transmission and in mothers
with advanced ﬁbrosis to prevent ﬂares. Viable treatment choices
are limited to lamivudine, tenofovir, and telbivudine. Of these,
lamivudine and tenofovir appear to be the therapeutic options
with reasonable human exposure and safety data in pregnancy
and we do see now an increasing number of data for the safety
of telbivudine, too.
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